Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence
Sajida Sabsabi,1 Elio Mikhael,2 Georges Jalkh,1 Gabrielle Macaron,1,3 Mary Rensel3 1Department of Neurology, Hotel Dieu de France Hospital, Saint Joseph University, Beirut, Lebanon; 2Department of Internal Medicine, Hotel Dieu de France Hospital, Saint Joseph University, Beirut, Lebanon; 3Mellen Cen...
Main Authors: | Sabsabi S, Mikhael E, Jalkh G, Macaron G, Rensel M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2022-05-01
|
Series: | Patient Preference and Adherence |
Subjects: | |
Online Access: | https://www.dovepress.com/clinical-evaluation-of-siponimod-for-the-treatment-of-secondary-progre-peer-reviewed-fulltext-article-PPA |
Similar Items
-
New possibilities of siponimod therapy in patients with secondary progressive multiple sclerosis
by: D. S. Kasatkin, et al.
Published: (2021-02-01) -
Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
by: Gajofatto A
Published: (2017-11-01) -
New possibilities for the therapy of secondary progressive multiple sclerosis
by: A. M. Petrov, et al.
Published: (2019-12-01) -
Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
by: Liesa Regner-Nelke, et al.
Published: (2022-11-01) -
Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action
by: Newshan Behrangi, et al.
Published: (2019-01-01)